UK markets closed

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5750-0.1050 (-2.24%)
As of 03:23PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-77,112
-71,169
-67,061
-56,624
-56,424
Depreciation & amortisation
808
833
744
674
217
Stock-based compensation
6,636
7,037
7,672
7,164
2,308
Change in working capital
-2,304
-3,082
2,012
85
-111
Accounts payable
351
-1,378
150
-675
2,098
Other working capital
-77,591
-70,973
-58,171
-48,550
-36,542
Other non-cash items
1,324
1,124
526
378
-
Net cash provided by operating activities
-77,436
-70,675
-57,761
-48,153
-35,974
Cash flows from investing activities
Investments in property, plant and equipment
-155
-298
-410
-397
-568
Purchases of investments
-272,595
-269,330
-151,993
-121,967
-177,922
Sales/maturities of investments
215,732
215,982
147,000
165,160
61,311
Net cash used for investing activities
-57,018
-53,646
-5,403
42,796
-117,179
Cash flows from financing activities
Common stock issued
-
85,647
56,137
0
115,972
Net cash used provided by (used for) financing activities
106,032
125,969
72,788
609
149,812
Net change in cash
-28,422
1,648
9,624
-4,748
-3,341
Cash at beginning of period
49,378
33,269
23,670
28,394
31,735
Cash at end of period
20,956
34,899
33,269
23,670
28,394
Free cash flow
Operating cash flow
-77,436
-70,675
-57,761
-48,153
-35,974
Capital expenditure
-155
-298
-410
-397
-568
Free cash flow
-77,591
-70,973
-58,171
-48,550
-36,542